Author:
Deng Xiaohu,Ren Pingda,Mai Wanping,Wang Yi,Zhang Yuanyang,Wu Hongbing,Xie Yinwei,Chen Huazhen
Publisher
Springer Science and Business Media LLC
Subject
Drug Discovery,Pharmaceutical Science,Agronomy and Crop Science,Ecology,Aquatic Science,General Medicine,Ecology, Evolution, Behavior and Systematics
Reference18 articles.
1. Chin HM, Lai DK, Falchook GS. Extracellular signal-regulated kinase (ERK) inhibitors in oncology Clinical trials. J Immunother Precis Oncol. 2019;2(1):10–6.
2. Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, et al. First-in-class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a Phase I dose-escalation and expansion study. Cancer Discov. 2018;8(2):185–95.
3. Buchbinder EI, Cohen JV, Haq R, Hodi FS, Lawrence DP, Giobbie-Hurder A, et al. A phase II study of ERK inhibition by ulixertinib (BVD-523) in metastatic uveal melanoma. J Clin Oncol. 2020;38(15):10036.
4. Pant S, Bendell JC, Sullivan RJ, Shapiro G, Millward M, Mi G, et al. A phase I dose escalation (DE) study of ERK inhibitor, LY3214996, in advanced (adv) cancer (CA) patients (pts). J Clin Oncol. 2019;37(15_suppl):3001.
5. Li L, Wu T, Feng J, Ren P, Liu Y. Inhibitors of ERK and methods of use. US Patent No. US-9624228-B2. Available from: https://pubchem.ncbi.nlm.nih.gov/patent/US-9624228-B2.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献